http://www.scommerce.com/tipd-social-networking-meets-stock-investing/ sCommerce.com - Social Commerce and Social Sourcing Trends Mon, 06 Feb 2012 06:49:00 +0000 hourly 1 http://wordpress.org/?v=3.0.3 http://www.scommerce.com/tipd-social-networking-meets-stock-investing/comment-page-1/#comment-677 mlgreen8753 Sat, 12 Sep 2009 08:35:22 +0000 http://www.scommerce.com/?p=1008#comment-677 Tip's is a good resource for stock investors to share their experience and opinion of particular stocks; however, I question how useful it would be for lesser known stocks. I could really use a second opinion on a stock I'm looking at right now. Mentor Capital (MNTR) has a 20% interest in Quantum Immunologics (QI), a biotech company in FDA approved trials for their new breast cancer treatment that exposes proteins found only on cancer cells in order to use the body’s immune system to focus on and attack cancer cells specifically. Unlike surgery, radiation, and chemotherapy, patients report only flu-like side effects. Mentor Capital intends to funnel more capital into QI. According to <a href="http://breastcancerinvesting.com/investor_call.shtml" rel="nofollow">BreastCancerInvesting.com</a>, buying Mentor Capital’s common stock at its current price of $2.65/share is like a risk-mitigated call option on QI’s cancer immunotherapy candidate which could pay off exponentially in terms of stock price gains. I haven't heard many outside opinions on the stock so something like Tip'd would be great. Tip's is a good resource for stock investors to share their experience and opinion of particular stocks; however, I question how useful it would be for lesser known stocks. I could really use a second opinion on a stock I'm looking at right now. Mentor Capital (MNTR) has a 20% interest in Quantum Immunologics (QI), a biotech company in FDA approved trials for their new breast cancer treatment that exposes proteins found only on cancer cells in order to use the body’s immune system to focus on and attack cancer cells specifically. Unlike surgery, radiation, and chemotherapy, patients report only flu-like side effects. Mentor Capital intends to funnel more capital into QI. According to BreastCancerInvesting.com, buying Mentor Capital’s common stock at its current price of $2.65/share is like a risk-mitigated call option on QI’s cancer immunotherapy candidate which could pay off exponentially in terms of stock price gains. I haven't heard many outside opinions on the stock so something like Tip'd would be great.

]]>